How GLP-1 Medications Are Reshaping the Food and Wellness Industries

For years, conversations about healthier eating have followed a familiar pattern: eat less sugar, choose more whole foods, watch portions, get enough protein and fiber. But the rapid rise of GLP-1 medications is introducing something very different into the equation. Instead of simply changing what people think they should eat, these medications can change appetite itself.

Originally developed to help manage type 2 diabetes, GLP-1 medications have become increasingly prominent in weight management. Drugs such as Wegovy and Zepbound work in part by helping people feel fuller for longer, which can significantly reduce how much they eat. And as their use expands, the effects are moving well beyond the doctor’s office.

They are beginning to reshape grocery carts, restaurant menus, product innovation and even the way wellness brands talk about nutrition. And there may be another, less obvious consequence: changing how we think about portions and food waste.

When Eating Less Changes What Matters

One of the most interesting shifts happening around GLP-1 use is that eating less doesn’t necessarily mean caring less about food. In many cases, it may mean expecting more from it.

Recent consumer research shows GLP-1 households are cutting back on categories such as sweets and salty snacks while shifting spending toward foods such as produce and protein. Overall grocery spending can decline, but where that money goes is changing.

That creates an interesting challenge for food companies. If someone is eating a smaller meal, every bite has to work a little harder.

Protein, fiber and nutrient density are becoming more important, while oversized portions may become less appealing. This doesn’t mean dessert, snacks, or comfort foods are disappearing. Far from it. But the definition of value may be changing from “How much am I getting?” to “What am I getting from this?”

Smaller Portions Could Finally Have Their Moment

For decades, bigger has often been positioned as better value in American food culture. GLP-1s may help challenge that assumption.

Consumers taking these medications are increasingly interested in smaller portions and greater flexibility when dining out. That could create opportunities extending well beyond people taking GLP-1s. Smaller, thoughtfully portioned meals may appeal to older consumers, people interested in healthier eating, and anyone who has ever looked at an enormous restaurant entrée and wondered why it could feed three people.

There is also a sustainability argument hiding in plain sight.

Restaurant portions that are larger than people want or need often end up in the trash. ReFED estimates that roughly 70% of restaurant and foodservice food waste comes from plate waste. Its research suggests that offering different portion sizes could potentially eliminate millions of tons of food waste each year.

So perhaps the rise of GLP-1s could help normalize something sustainability advocates have talked about for years: serving people an amount they actually want to eat.

Could Smaller Appetites Mean Less Waste?

The answer isn’t quite that simple.

Research on food waste among GLP-1 users found that about one-quarter initially reported increased food waste after starting medication. That makes sense. Imagine shopping and cooking the way you always have, only to discover that you can no longer finish the same amount.

But the research found something else that is particularly interesting: people who had been using the medications longer were less likely to report increased food waste.

In other words, habits may catch up with appetite.

People may eventually learn to buy less, prepare smaller meals, and reconsider what constitutes a normal portion. If those behaviors become more widespread, the implications could reach beyond household garbage cans.

Producing food that ultimately isn’t eaten consumes land, water, energy, packaging, and transportation. Recent research on GLP-1s and sustainability suggests that lower food consumption could reduce some environmental pressures, although researchers caution that the real-world impact will depend on how consumers and the food industry respond.

GLP-1s aren’t a sustainability solution. But they may unintentionally force a useful conversation about how much food we produce, purchase, serve—and throw away.

Wellness Is Expanding Around the GLP-1 Consumer

The ripple effect is equally significant for the wellness industry.

Eating substantially less can make adequate nutrition more challenging. Protein has received particular attention because maintaining muscle mass is important during weight loss. Fiber, hydration and micronutrients are also becoming part of the conversation.

That is opening a market for protein products, fiber supplements, hydration solutions, vitamins and other products positioned around nutritional support.

But there is an important line for wellness brands to navigate.

Not every person taking a GLP-1 needs the same nutritional support, and supplements should not be assumed to be automatically necessary simply because someone uses one of these medications. As interest grows, responsible communication will matter just as much as product innovation.

There is a difference between helping consumers meet changing nutritional needs and using the popularity of GLP-1s as the latest marketing hook.

Less, But Better?

Perhaps the most lasting impact of GLP-1 medications won’t be a particular protein shake, a smaller frozen dinner, or a supplement. It may be the broader shift they are accelerating in how consumers think about consumption.

For much of modern food marketing, success has been built around encouraging people to want more: bigger portions, more snacks, more flavors, more eating occasions.

GLP-1s complicate that model.

When appetite decreases, consumers may become more selective. Taste still matters, but so do quality, nutrition, convenience and how a food makes them feel.

And that mindset could resonate with people who never take a GLP-1 medication at all. Smaller portions, nutrient-dense foods, less waste and more thoughtful consumption fit into wellness and sustainability trends that were already gaining momentum.

GLP-1 medications may simply be accelerating them.

Perhaps the bigger question for the food and wellness industries isn’t how to sell to the “GLP-1 consumer.” It is what this rapidly growing group is telling us about where consumer expectations are headed.

Less may no longer mean sacrifice.

It may mean making what we eat—and what we produce—count.